These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23468127)

  • 1. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
    Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
    Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinomas: evolution after menopause.
    Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
    Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
    Burlacu MC; Maiter D; Duprez T; Delgrange E
    Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).
    Elenkova A; Atanassova I; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2013 Sep; 169(3):299-306. PubMed ID: 23801826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.
    Smith MV; Laws ER
    Neurosurgery; 1994 May; 34(5):834-9; discussion 839. PubMed ID: 8052379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant prolactinomas in women.
    Delgrange E; Raverot G; Bex M; Burman P; Decoudier B; Devuyst F; Feldt-Rasmussen U; Andersen M; Maiter D
    Eur J Endocrinol; 2014 Jan; 170(1):31-8. PubMed ID: 24088550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
    BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.